Cancer Genetics (CGIX) Tops Q2 EPS by 5c

August 10, 2016 9:16 AM EDT
Get Alerts CGIX Hot Sheet
Trade CGIX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Cancer Genetics (NASDAQ: CGIX) reported Q2 EPS of ($0.28), $0.05 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $7 million versus the consensus estimate of $6.5 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment